Shares of Oxford Biomedica plc (LON:OXB - Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 389.64 ($4.83) and traded as high as GBX 413.50 ($5.13). Oxford Biomedica shares last traded at GBX 410 ($5.09), with a volume of 155,898 shares trading hands.
Oxford Biomedica Stock Performance
The business has a 50 day moving average of GBX 418.20 and a 200-day moving average of GBX 390.81. The company has a current ratio of 2.35, a quick ratio of 1.67 and a debt-to-equity ratio of 154.88. The firm has a market capitalization of £420.91 million, a P/E ratio of -277.43 and a beta of 1.09.
Oxford Biomedica Company Profile
(
Get Free Report)
Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
Further Reading
Before you consider Oxford Biomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.
While Oxford Biomedica currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
